Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Prostatic Neoplasms 3Breast Neoplasms 3Male Urogenital Diseases 2Small Cell Lung Carcinoma 1Polycystic Ovary Syndrome 1Lymphoma, Follicular 1Lymphedema 1Lung Neoplasms 1Head and Neck Neoplasms 1Fibrosis 1Erectile Dysfunction 1Drug-Related Side Effects and Adverse Reactions 1Crohn Disease 1Colorectal Neoplasms 1Colitis, Ulcerative 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms, Male 1Brain Neoplasms 1

Interventions

Tadalafil 2udenafil 1mirabegron 1bicalutamide 1alpha-Tocopherol 1Vitamin E 1Tamoxifen 1Sildenafil Citrate 1Pentoxifylline 1Long-Term Synaptic Depression 1GPI 1485 1Erythropoietin 1Dutasteride 1Atorvastatin 1Arginine 1ArginMax 1Anastrozole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Erectile Dysfunction × Vitamin E × Clear all
NCT03830164 2023-10-17

Pentoxifylline, Atorvastatin, and Vitamin E in Treating Patients With Erectile Dysfunction After Radiation Therapy for Prostate Cancer

M.D. Anderson Cancer Center

Phase 2 Completed
14 enrolled 9 charts

Erectile Dysfunction

Data powered by HemOnc (CC BY 4.0) Colophon âš¡